Auron Therapeutics, Inc.

Today, we proudly presented preclinical data for our lead program at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA. This development highlights the dose-dependent survival advantage of AUTX-703 in a patient-derived AML model. These findings validate the strength of our AURIGIN™ platform, which combines AI and machine learning to identify innovative oncology targets. With IND submissions on track before year-end and plans to move into the clinic in 2025, we’re excited to bring next-generation cancer therapies closer to reality. 📄 Read the full press release here: https://lnkd.in/eFgXfNtC #ASH

We're very excited to be presenting pre-clinical data on AUTX-703 at the American Society of Hematology (ASH) Annual Meeting. #ASH #Leukemia

The Auron team is excited to be presenting at the EORTC-NCI-AACR (ENA) Symposium and Prostate Cancer Foundation (PCF) Annual Scientific Retreat this week #ENASymp2024 #PCF

Thrilled to have presented data at #ACSFall2024, highlighting the strength of @AuronTherapeutics' #medicinalchemistry capabilities in #cancer drug discovery and development. Our team is leveraging deep expertise to advance a pipeline of next-generation #targetedtherapies to help transform #oncology treatment in the future.

We’re excited to welcome @SergeMesserlian to the @Auron Board! We are confident that Serge’s insights and leadership will be invaluable as we continue to grow and innovate. We look forward to achieving great things together, Serge!   #Welcome #BoardofDirectors #CancerResearch 

I am pleased to join Kate Yen and the Board of Directors at Auron Therapeutics, Inc. The Company pioneered its AURIGIN™ platform, which uses AI and machine learning to compare normal cell states with cancerous cell states, to identify novel cancer targets, optimal development models, and biomarkers to facilitate proper patient selection. Using AURIGIN, Auron is building a pipeline of small molecule targeted therapies, led by AUTX-703, which is being developed for the treatment of both solid tumors, including small cell lung cancer and neuroendocrine prostate cancer, and hematologic malignancies, including acute myeloid leukemia. We have significant opportunity ahead to make an impact on the lives of patients!

Excited to present an overview of our AURIGIN platform at the AI in Biomedicine Keystone Symposia on May 3rd! We use AURIGIN to identify, prioritize, and validate key driver of cancer cell states, and then apply deep structure-based drug design to develop novel, targeted small molecule therapies. Join us as we combat the complex and evolving nature of cancer! #AURIGIN #AI #CancerResearch #KeystoneSymposia

We’re excited to be at the American Association for Cancer Research's annual meeting, highlighting our platform and sharing our progress in developing next-generation targeted therapies for patients. Look for our presentations and reach out to connect with us!   #AACR #AACR24 #AACR2024 #CancerResearch

Meet AURIGIN, our revolutionary platform for drug discovery. This proprietary technology is designed to identify and facilitate the development of novel targets that can treat the most challenging aspects of cancer biology. AURIGIN is our beacon in the quest for new, effective cancer treatments, leading us towards a better future for patients. Stay tuned as we redefine the boundaries of possibility!   #drugdiscovery #InnovateToCure #cancerresearch

What is cell state plasticity – and why is it a critical pathway for cancer?   In normal, healthy development, cells divide rapidly and proliferate to form the body’s tissues and organs. Once cells evolve to their final cell type, they lose the ability to proliferate. Cancer hijacks this process, keeping cells in the plastic state to use that high proliferation ability to grow tumors.   At Auron, we’re identifying and targeting the drivers of those altered cellular states, reverting cancer cells from a proliferative plastic state to a normal, dormant state to stop the growth of the tumor.   Read more about cell state plasticity here: https://bit.ly/4bLFlcd  #science #cancerresearch #biotech